EXACT Sciences Corporation (OQ:EXAS)

Business Focus: Biotechnology & Medical Research

Sep 23, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Exact Sciences, Plus Therapeutics, or Arcadia Biosciences?
NEW YORK, Sept. 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, EXAS, PSTV, and RKDA....
Sep 23, 2019 05:45 am ET
Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
MADISON, Wis., Sept. 23, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older. The decision comes at a critical time when the incidence of colorectal cancer is on the rise among American adults under the age of 50.[i] ...
Sep 19, 2019 08:35 am ET
Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE
MADISON, Wis., Sept. 19, 2019 /PRNewswire/ -- Exact Sciences is a member of the 2019 Best Workplaces for Women list, an honor given by Great Place to Work® and FORTUNE to employers providing supportive, inclusive workplaces. To determine the Best Workplaces for Women, Great Place to Work® analyzed anonymous survey feedback representing more than 4.6 million employees at Great Place to Work-CertifiedTM organizations. Employees responded to more than 60 survey questions anonymously rating their employers.  ...
Sep 10, 2019 06:00 am ET
Cologuard® Helps More People Get Screened In A Cost-Effective Way
MADISON, Wis., Sept. 10, 2019 /PRNewswire/ -- (NASDAQ: EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those tested being previously unscreened.  Not only is Cologuard increasing the number of screened Americans, peer reviewed data shows that Cologuard is a cost-effective alternative for people at average risk for colorectal cancer (CRC). ...
Aug 30, 2019 09:15 am ET
Exact Sciences to participate in September investor conference
MADISON, Wis., Aug. 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast....
Aug 02, 2019 05:18 pm ET
GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Genomic Health, Inc. (NasdaqGS: GHDX) to Exact Sciences Corp. (NasdaqGS: EXAS).  Under the terms of the proposed transaction, shareholders of Genomic will receive only $27.50 in cash and the equivalent of $44.50 in shares of Exact Sciences for each share of Genomic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the co...
Aug 02, 2019 06:00 am ET
Exact Sciences to participate in August investor conference
MADISON, Wis., Aug. 2, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast....
Jul 29, 2019 08:00 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection with the proposed acquisition of the Company by Exact Science Corp. ("EXAS") (NASDAQ: EXAS).  Under the terms of the agreement, Genomic Health shareholders will receive $27.50 in cash and $44.50 in EXAS shares for each GHDX share held, representing consideration of $72.00 per GHDX share.  ...
Jul 29, 2019 02:42 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Genomic Health, Inc. (“Genomic Health” or the “Company”) (NASDAQGS: GHDX) stock prior to July 29, 2019. You are hereby notified that...
Jul 29, 2019 07:01 am ET
Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000
MADISON, Wis., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $199.9 million and screened approximately 415,000 people with Cologuard during the quarter ended June 30, 2019. Second-quarter 2019 revenue and test volume grew 94 percent and 93 percent, respectively, from the same period of 2018. ...
Jul 29, 2019 07:00 am ET
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and Genomic Health, Inc. (NASDAQ: GHDX) today announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to be completed by the end of 2019....
Jul 17, 2019 06:00 am ET
Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019
MADISON, Wis., July 17, 2019 /PRNewswire/ -- The more than 2,400 people of Exact Sciences work every day to create life-changing innovations in earlier cancer detection. In the process, they also created a certifiably great place to work. ...
Jul 09, 2019 06:00 am ET
Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls
MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results....
May 20, 2019 08:56 am ET
Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. ...
May 17, 2019 05:30 am ET
Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes....
May 01, 2019 06:00 am ET
Exact Sciences to participate in May investor conferences
MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast....
Apr 30, 2019 04:05 pm ET
First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
MADISON, Wis., April 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $162.0 million and screened approximately 334,000 people with Cologuard during the quarter ended March 31, 2019. First-quarter 2019 revenue and test volume both grew 79 percent from the same period of 2018....
Apr 08, 2019 06:00 am ET
Exact Sciences schedules first-quarter 2019 earnings call
MADISON, Wis., Apr. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. ...
Mar 19, 2019 08:00 am ET
Kathleen Sebelius Appointed to Exact Sciences Board
MADISON, Wis., March 19, 2019 /PRNewswire/ -- Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services (HHS) from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (Nasdaq: EXAS), a leader in detecting cancer at its earliest, most treatable stages....
Mar 05, 2019 11:14 pm ET
Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027
MADISON, Wis., March 6, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount.  The Company has granted the underwriter a 30-day option to purchase up to an additional $97.5 million aggregate principal amount of the Notes solely to cover over-allotments, if any....
Mar 05, 2019 03:01 pm ET
Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027
MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes.  Concurrently with this offering, in separate transactions, the Company also...
Mar 04, 2019 07:00 am ET
Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst R
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eaton Corporation, PLC (NYSE:ETN), Kite Realty Group Trust (NYSE:KRG),...
Mar 01, 2019 05:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast....
Feb 27, 2019 05:00 am ET
Cologuard Helps Screen Two Million People for Colorectal Cancer
MADISON, Wis., Feb. 27, 2019 /PRNewswire/ -- In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the groundbreaking product with Mayo Clinic, processed more than one million Cologuard tests in the last year alone. Nearly half of the people screened with Cologuard had not previously been screened for colorectal cancer, the second leading cause of cancer death in the United States.i...
Feb 21, 2019 03:05 pm ET
Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard
MADISON, Wis., Feb. 21, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $454.5 million and completed approximately 934,000 Cologuard tests during the year ended Dec. 31, 2018. Full-year 2018 revenue and Cologuard test volume grew 71 percent and 64 percent from 2017, respectively. ...
Feb 20, 2019 04:06 pm ET
Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors
CUTERA, INC., (Nasdaq: CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced today the appointment of two new independent members to its Board of...
Feb 04, 2019 05:00 am ET
Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
MADISON, Wis., Feb. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Feb. 21, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. ...
Jan 28, 2019 07:30 am ET
Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolida
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rollins, Inc. (NYSE:ROL), Hospitality Properties Trust (NASDAQ:HPT), Exact...
Jan 06, 2019 06:00 pm ET
Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018
MADISON, Wis., Jan. 6, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $142.5 million and $143.5 million for the fourth quarter ended Dec. 31, 2018, an increase of 64 percent from the same quarter of 2017. The company completed approximately 292,000 Cologuard tests during the fourth quarter of 2018, which represents 66-percent growth from the same period of 2017....
Dec 20, 2018 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Dec. 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast....
Nov 09, 2018 05:00 am ET
Exact Sciences to participate in two November investor conferences
MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast....
Nov 05, 2018 07:25 am ET
Report: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Develop
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MRC Global Inc. (NYSE:MRC), Exact Sciences Corporation (NASDAQ:EXAS),...
Oct 30, 2018 04:05 pm ET
Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter
MADISON, Wis., Oct. 30, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $118.3 million and screened approximately 241,000 people with Cologuard during the quarter ended September 30, 2018. Third-quarter 2018 revenue and Cologuard test volume grew by 63 percent and 49 percent, respectively, from the same period of 2017. ...
Oct 18, 2018 07:00 am ET
Exact Sciences Strengthens Pipeline Capabilities with Acquisition of Biomatrica, a Leading Provider of Biological Sample Preservation Technology
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica's proprietary technolog...
Oct 08, 2018 06:00 am ET
Exact Sciences schedules third-quarter 2018 earnings call
MADISON, Wis., Oct. 8, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third-quarter 2018 financial results after the close of the U.S. financial markets on Oct. 30, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. ...
Oct 04, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Ashland Global, Pattern Energy Group, Jacobs Engineering Group, Olin, Exact Sciences, and Comcast — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Pattern Energy Group Inc....
Aug 31, 2018 06:00 am ET
Exact Sciences to participate in September investor conferences
MADISON, Wis., Aug. 31, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during September and invited investors to participate by webcast....
Aug 22, 2018 06:15 am ET
Exact Sciences to host conference call and webcast to discuss its Cologuard co-promotion agreement with Pfizer
MADISON, Wis., Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will host a conference call and webcast on Wednesday, Aug. 22, 2018, at 8:00 a.m. ET to discuss details of its co-promotion agreement with Pfizer. Kevin Conroy, the company's chairman and CEO; Jeff Elliott, chief financial officer; and Mark Stenhouse, president, Cologuard, will make remarks and take questions on the call. Nick Lagunowich, regional president North America, Pfizer Internal Medicine, will also make remarks on the call....
Aug 22, 2018 06:00 am ET
Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®
MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Pfizer Inc. (NYSE: PFE) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact Sciences' sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign.  ...
Aug 13, 2018 09:00 am ET
Green Bay Packers and Cologuard Launch "Crossing the 50" Colon Cancer Awareness Campaign
GREEN BAY, Wis. and MADISON, Wis., Aug. 13, 2018 /PRNewswire/ -- When the Green Bay Packers cross the 50-yard line this season, it will be meaningful both on and off the field....
Aug 06, 2018 06:00 am ET
Exact Sciences to participate in Canaccord Genuity Growth Conference
MADISON, Wis., Aug. 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during August and invited investors to participate by webcast....
Aug 02, 2018 11:00 am ET
Tom Lehman Joins Forces with Fight Colorectal Cancer to Raise Awareness of Nation's Second-Leading Cause of Cancer Deaths
BLAINE, Minn., Aug. 2, 2018 /PRNewswire/ -- Longtime PGA TOUR professional and colon cancer survivor, Tom Lehman, is teaming up with Fight Colorectal Cancer (Fight CRC) to help raise awareness of the nation's second-deadliest cancer. The one-year agreement, supported by Exact Sciences (NASDAQ: EXAS), will feature Lehman wearing the Fight CRC logo on his hat, numerous public appearances, and a public service announcement campaign highlighting the importance of early detection and the options available for colon cancer screening, including accurate, non-invasive options....
Aug 01, 2018 04:05 pm ET
Cologuard® revenue increased 78 percent to $103 million during second quarter
MADISON, Wis., Aug. 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $102.9 million and completed approximately 215,000 Cologuard tests during the quarter ended June 30, 2018. Second-quarter 2018 revenue and Cologuard test volume grew by 78 percent and 59 percent, respectively, from the same period of 2017. ...
Jul 09, 2018 04:15 pm ET
Exact Sciences to host annual meeting, second-quarter 2018 results webcasts and calls
MADISON, Wis., July 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and to discuss its second-quarter 2018 financial results....
Jun 26, 2018 11:00 am ET
Nurse Practitioners are Critical Source of Colorectal Cancer Screening Information for Patients, Survey Shows
MADISON, Wis., June 26, 2018 /PRNewswire/ -- Exact Sciences today announced results of HealthyWomen's National Colorectal Cancer SNAPP (Screening KNowledge and Practice Patterns) Survey, in partnership with the American Association of Nurse Practitioners (AANP). This survey of 358 nurse practitioners (NPs) showed they are highly engaged in colorectal cancer (CRC) screening, both personally and on behalf of their patients. It also revealed the need for increased awareness of the multitarget stool DNA test, a recommended CRC screening option....
Jun 26, 2018 07:40 am ET
Research Report Identifies PDL BioPharma, TEGNA, Patterson Companies, Boardwalk Pipeline Partners, Exact Sciences, and Berkshire Hathaway with Renewed Outlook — Fundamental Analysis, Calculating Forwa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDL BioPharma, Inc. (NASDAQ:PDLI), TEGNA Inc. (NYSE:TGNA), Patterson...
Jun 19, 2018 09:00 am ET
Cologuard Challenge Expands to AmFam Championship Urging PGA TOUR Champions Fans to Get Screened for Colon Cancer
MADISON, Wis., June 19, 2018 /PRNewswire/ -- The national colon cancer screening movement led by golfer Jerry Kelly will be front and center when the PGA TOUR Champions comes to University Ridge Golf Course June 22-24, 2018 for the American Family Insurance Championship (AmFam Championship). ...
Jun 08, 2018 08:00 am ET
Exact Sciences Announces Upsizing and Pricing of 1.0% Convertible Senior Notes Due 2025
MADISON, Wis., June 8, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 1.0% Convertible Senior Notes due 2025 (the "Notes") and upsized the offering from $150 million to $190 million aggregate principal amount, providing for total gross proceeds of $202.4 million, excluding accrued interest.  The initial public offering price for the Notes will be 106.5% of face value plus accrued interest from January 17, 2018.  The Notes issuance is a reopening of, and will be fully fungible and form a single series with,...
Jun 07, 2018 04:01 pm ET
Exact Sciences Announces Offering of 1.0% Convertible Senior Notes Due 2025
MADISON, Wis., June 7, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced an underwritten public offering of $150 million aggregate principal amount of its 1.0% convertible senior notes due 2025 (the "Notes") in a registered public offering. The Company also plans to grant to the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest. The Notes issuance is a reopening of, and will be part of the same series as, the $690 mi...
Jun 05, 2018 04:30 pm ET
Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma
WASHINGTON, June 5, 2018 /PRNewswire/ -- Researchers at Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in the liver.1 The researchers detailed their findings during a presentation today at Digestive Disease Week, the world's largest gathering of gastroenterologists and scientists in the field. ...
Jun 01, 2018 06:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during June and invited investors to participate by webcast....
May 08, 2018 07:20 am ET
Recent Analysis Shows Boardwalk Pipeline Partners, Chegg, CommScope Holding, Exact Sciences, HollyFrontier, and Hecla Mining Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Boardwalk Pipeline Partners L.P. (NYSE:BWP), Chegg, Inc. (NYSE:CHGG),...
May 03, 2018 09:00 am ET
Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer
MILWAUKEE and MADISON, Wis., May 3, 2018 /PRNewswire/ -- Colon cancer cut short the life of legendary football coach Vince Lombardi at the age of 57 and, nearly 50 years later, remains the number two cancer killer in the United States. Now, the foundation bearing his name and one of the country's premier cancer diagnostics companies are teaming up to fight back. ...
May 01, 2018 06:00 am ET
Exact Sciences to participate in two investor conferences during May
MADISON, Wis., May 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during May and invited investors to participate by webcast....
Apr 30, 2018 09:30 am ET
Must See Stock Score Reports for Charter Communications, Exact Sciences, Nike, Sprint, and Snap Inc.
CHICAGO, April 30, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHTR, EXAS, NKE, S, and SNAP....
Apr 26, 2018 04:05 pm ET
Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000
MADISON, Wis., April 26, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $90.3 million and completed approximately 186,000 Cologuard tests during the quarter ended Mar. 31, 2018. First-quarter 2018 revenue and Cologuard test volume both grew 87 percent from 2017. ...
Apr 09, 2018 06:00 am ET
Exact Sciences schedules first-quarter 2018 earnings call
MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2018 financial results after the close of the U.S. financial markets on April 26, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress. ...
Mar 20, 2018 06:00 am ET
Mark Stenhouse to join Exact Sciences as President, Cologuard
MADISON, Wis., March 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), the company that developed and commercialized Cologuard®, the only FDA-approved, noninvasive stool DNA-based test for early detection of colorectal cancer, today announced that Mark Stenhouse has been appointed to the new role of president, Cologuard. Stenhouse, vice president, U.S. Immunology at AbbVie, will assume this new position on April 2, 2018. ...
Mar 19, 2018 09:00 am ET
Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Cancer
MADISON, Wis., March 19, 2018 /PRNewswire/ -- Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill's recovery from breast cancer.  As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign ...
Mar 06, 2018 07:50 am ET
Detailed Research: Economic Perspectives on Exact Sciences, KapStone Paper and Packaging, Spirit Realty Capital, KLA-Tencor, New Residential Investment, and Brookdale Senior Living — What Drives Growt
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Exact Sciences Corporation (NASDAQ:EXAS), KapStone Paper...
Mar 06, 2018 05:00 am ET
Mayo Clinic's Dr. Paul Limburg to join Exact Sciences medical leadership
MADISON, Wis., March 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been appointed the company's co-chief medical officer. Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. He is also a co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center. ...
Mar 01, 2018 01:00 pm ET
Jerry Kelly Issues Cologuard Challenge, Urging Fellow PGA TOUR Champions Players to Get Screened for Colon Cancer
TUCSON, Ariz., March 1, 2018 /PRNewswire/ -- Three-time PGA TOUR Champions winner Jerry Kelly is raising the bar on his competitors when it comes to colon cancer screening. At a players-only meeting before the Cologuard Classic today, Kelly urged his friends and competitors to get screened for colon cancer....
Mar 01, 2018 05:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., March 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during March and invited investors to participate by webcast....
Feb 28, 2018 02:29 pm ET
Tucson Conquistadores and Cologuard Present Check to Vince Lombardi Cancer Foundation
TUCSON, Ariz., Feb. 28, 2018 /PRNewswire/ -- The PGA TOUR Champions professionals playing in this week's tournament haven't officially teed off yet, but the Cologuard Classic is already giving back....
Feb 27, 2018 10:00 am ET
Feb 26, 2018 06:00 am ET
More than 1 Million Screened for Colorectal Cancer with Cologuard
MADISON, Wis., Feb. 26, 2018 /PRNewswire/ -- More than 1 million patients have been screened for colorectal cancer with Cologuard, Exact Sciences Corp. (Nasdaq: EXAS), the maker of the test, announced today.  This milestone comes less than four years after the noninvasive screening test was approved by the FDA and covered by Medicare, making it one of the most quickly adopted diagnostic technologies of all time.  ...
Feb 22, 2018 03:05 pm ET
Cologuard® revenue increased 168 percent to $266 million
MADISON, Wis., Feb. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $266 million and completed approximately 571,000 Cologuard tests during the year ended Dec. 31, 2017. Full-year 2017 revenue and Cologuard test volume grew 168 percent and 134 percent from 2016, respectively. ...
Feb 22, 2018 01:00 pm ET
Exact Sciences Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Exact Sciences Corporation (NASDAQ: EXAS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 5:00 PM Eastern Time.
Feb 08, 2018 05:00 am ET
Exact Sciences schedules fourth-quarter, full-year 2017 earnings call
MADISON, Wis., Feb. 8, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2017 financial results after the close of the U.S. financial markets on Feb. 22. Following the release, company management will host a webcast and conference call at 5 p.m. Eastern time to discuss financial results and business progress. ...
Feb 01, 2018 05:00 am ET
Exact Sciences to participate in Leerink Partners 7th Annual Global Healthcare Conference
MADISON, Wis., Feb. 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during February and invited investors to participate by webcast....
Jan 26, 2018 08:30 am ET
New Research: Key Drivers of Growth for Coca-Cola Bottling Co. Consolidated, McGrath RentCorp, Exact Sciences, Healthcare Trust of America, Gramercy Property Trust, and Apollo Commercial Real Estate F
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), McGrath...
Jan 11, 2018 08:47 pm ET
Exact Sciences Announces Upsize and Pricing of $600 Million of 1.0% Convertible Senior Notes Due 2025
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 1.0% convertible senior notes due 2025 (the "Notes"), and upsized the offering from $500 million to $600 million aggregate principal amount, pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90 million aggregate principal amount of Notes. The closing of the offering ...
Jan 11, 2018 03:01 pm ET
Exact Sciences Announces Offering of $500 Million Convertible Senior Notes Due 2025
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced an underwritten public offering of $500 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $75 million aggregate principal amount of Notes.  The Company intends to use the net proceeds of this offering for general corporate and working ca...
Jan 07, 2018 12:45 pm ET
Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017
MADISON, Wis., Jan. 7, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $86.9 million and $87.9 million for the fourth quarter ended Dec. 31, 2017, an increase of 148 percent from the same quarter of 2016. The company completed approximately 176,000 Cologuard tests during the fourth quarter of 2017, 115-percent growth from the same period of 2016....
Dec 20, 2017 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Dec. 20, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that its executives will be presenting at the following investor conference and invited investors to participate by webcast....
Nov 09, 2017 08:10 am ET
Recent Analysis Shows Phillips 66, Exact Sciences, PPG Industries, Citrix, KBR, and Chegg Market Influences – Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Phillips 66 (NYSE:PSX), Exact Sciences Corporation...
Nov 08, 2017 02:00 pm ET
Nov 02, 2017 07:00 am ET
Exact Sciences to participate in two investor conferences during November
MADISON, Wis., Nov. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during November....
Oct 30, 2017 05:05 pm ET
Cologuard® revenue increased 158 percent to $73 million during third quarter
MADISON, Wis., Oct. 30, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $72.6 million and completed approximately 161,000 Cologuard tests during the quarter ended Sept. 30, 2017. Third-quarter 2017 revenue and completed Cologuard test volume grew 158 percent and 136 percent, respectively, from the same period of 2016. ...
Oct 24, 2017 07:00 am ET
Exact Sciences reschedules third-quarter 2017 earnings call to Oct. 30
MADISON, Wis., Oct. 24, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third-quarter 2017 financial results after the close of the U.S. financial markets on Oct. 30. Following the release, the company's management will host a webcast and conference call at 5 p.m. Eastern time to discuss financial results and business progress. The call is being rescheduled from the previously announced date of Oct. 31 solely to accommodate requests received from several investors who indicated a desire to spend Halloween with their families....
Oct 10, 2017 07:00 am ET
Exact Sciences schedules third-quarter 2017 earnings call
MADISON, Wis., Oct. 10, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third-quarter 2017 financial results after the close of the U.S. financial markets on Oct. 31. Following the release, the company's management will host a webcast and conference call at 5 p.m. Eastern time to discuss financial results and business progress. ...
Aug 30, 2017 07:00 am ET
Exact Sciences to participate in Baird Global Healthcare Conference
MADISON, Wis., Aug. 30, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Baird Global Healthcare Conference on Wednesday, Sept. 6....
Aug 01, 2017 07:00 am ET
Exact Sciences to participate in Canaccord Genuity Growth Conference
MADISON, Wis., Aug. 1, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the 37th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 9....
Jul 25, 2017 05:05 pm ET
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
MADISON, Wis., July 25, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter 2017 revenue and completed Cologuard test volume grew 172 percent and 149 percent from the same period of 2016, respectively. ...
Jul 21, 2017 05:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., July 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 145,348 shares of common stock to 167 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in a...
Jul 10, 2017 07:00 am ET
Exact Sciences to host second-quarter 2017 results, annual meeting webcasts and calls
MADISON, Wis., July 10, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls to discuss its second-quarter 2017 financial results and of its annual stockholders meeting....
Jun 22, 2017 05:05 pm ET
Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening
MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening.  Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk. ...
Jun 07, 2017 08:46 am ET
Exact Sciences Announces Pricing of Public Offering of Common Stock
MADISON, Wis., June 7, 2017 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced the pricing of its previously announced underwritten public offering of common stock. The Company is selling 7,000,000 shares of common stock through the underwriters at a public offering price of $35.00 per share. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares. The offering is being underwritten by Jefferies LLC, BofA Merrill Lynch and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, William Blair ...
Jun 06, 2017 05:02 pm ET
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
MADISON, Wis., June 6, 2017 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, BofA Merrill Lynch and Robert W. Baird & Co. Incorporated as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares....
Jun 01, 2017 07:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., June 1, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June....
May 19, 2017 05:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., May 19, 2017 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 86,098 shares of common stock to 89 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in acco...
May 15, 2017 05:49 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Exact Sciences Corporation (EXAS)
NEW YORK, May 15, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Exact Sciences Corporation ("Exact" or the "Company") (NASDAQ: EXAS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/exas. ...
May 15, 2017 01:59 pm ET
EXACT (EXAS) ALERT: J&W Investigates Exact Sciences; Encourages Investors to Contact the Firm
SAN DIEGO, May 15, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Exact Sciences (NASDAQ: EXAS) violated federal laws. ...
May 01, 2017 07:00 am ET
Exact Sciences to participate in Bank of America Merrill Lynch Healthcare Conference
MADISON, Wis., May 1, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas....
Apr 27, 2017 07:00 am ET
Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively. ...
Apr 04, 2017 07:00 am ET
CMS includes Cologuard in updated Medicare Advantage Star Ratings
MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test....
Mar 31, 2017 07:00 am ET
Exact Sciences to host first-quarter 2017 results webcast and call
MADISON, Wis., March 31, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on April 27, 2017, to discuss its first-quarter 2017 financial results and commercial accomplishments....
Mar 17, 2017 05:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., March 17, 2017 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 85,421 shares of common stock to 77 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in ac...
Mar 03, 2017 06:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., March 3, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during March....
Mar 01, 2017 05:31 pm ET
Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test
MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages....
Feb 21, 2017 06:00 am ET
Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase
MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively. ...
Feb 02, 2017 06:00 am ET
CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings
MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test....
Feb 01, 2017 06:00 am ET
Exact Sciences to participate in Leerink Partners Global Healthcare Conference
MADISON, Wis., Feb. 1, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the 6th Annual Leerink Partners Global Healthcare Conference in New York....
Jan 26, 2017 06:00 am ET
Exact Sciences to host fourth-quarter, full-year 2016 results webcast and call
MADISON, Wis., Jan. 26, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Feb. 21, 2017, to discuss its fourth-quarter and full-year 2016 financial results and commercial accomplishments. Exact Sciences' management also will discuss the company's 2017 priorities, including its product pipeline....
Jan 13, 2017 04:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., Jan.13, 2017 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 53,275 shares of common stock to 45 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in acco...
Jan 10, 2017 09:31 am ET
Investors: Covered-Call Reports for Advanced Micro Devices, Bank of America, Exact Sciences, Ford and Hewlett-Packard
CHICAGO, Jan. 10, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BAC, EXAS, F, and HPQ....
Jan 08, 2017 06:00 pm ET
Exact Sciences to report $99 million in revenues, 150 percent growth for 2016
MADISON, Wis., Jan. 8, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the company expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, an increase of 142 percent from the same quarter of 2015. The company completed approximately 82,000 Cologuard tests during the fourth quarter of 2016, which represents growth of 114 percent from the same period of 2015....
Jan 05, 2017 08:22 am ET
Cologuard Earns Positive Review from Blue Cross Blue Shield Association
MADISON, Wis., Jan. 5, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Blue Cross Blue Shield Association's (BCBSA) Center for Clinical Effectiveness "Evidence Street" recently released a positive review of Cologuard to its members.  BCBSA is a national federation of 36 Blue Cross and Blue Shield companies that insure one in three Americans. This continues the positive momentum for Cologuard, as coverage increased by 67 percent in 2016 and nearly 163 million Americans are now in health plans that cover the non-invasive colorectal cancer screening option. ...
Jan 03, 2017 06:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 3, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the 35th Annual J.P. Morgan Healthcare Conference in San Francisco....
Dec 12, 2016 06:00 am ET
Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Humana Inc. agreed to cover Cologuard as an in-network service for its members, effective January 1, 2017. Under terms of the agreement, Cologuard will be available to most Humana beneficiaries with no co-pay.  Humana covers nearly 10 million beneficiaries and is the nation's fifth largest commercial insurer.   ...
Nov 18, 2016 04:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., Nov. 18, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 47,704 shares of common stock to 40 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in acco...
Nov 08, 2016 04:05 pm ET
Exact Sciences Appoints Jeff Elliott Chief Financial Officer
MADISON, Wis., Nov. 8, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Jeff Elliott as chief financial officer.  Mr. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences as vice president, business development and strategy, in June 2016 and will begin his new role effective immediately.   ...
Nov 08, 2016 03:05 pm ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 8, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during November....
Oct 28, 2016 07:00 am ET
Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product
MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition....
Oct 26, 2016 07:00 am ET
Exact Sciences Completes 68,000 Cologuard Tests During the Third Quarter
MADISON, Wis., Oct. 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $28.1 million during the third quarter ended Sept. 30, 2016, an increase of 123 percent from $12.6 million in the third quarter of 2015.  The company completed approximately 68,000 Cologuard tests during the quarter, an increase of approximately 100 percent from the same quarter of 2015. Since the launch of Cologuard and through the end of the third quarter of 2016, nearly 50,000 providers have ordered the test....
Oct 17, 2016 07:00 am ET
Cologuard® Covered for TRICARE Beneficiaries
MADISON, Wis., Oct. 17, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now covered under TRICARE's preventive services policies for use every three years without patient coinsurance, copayments or deductibles.  The update was made after TRICARE's review of its screening coverage policies to align them with the preventive services coverage mandate of the Affordable Care Act.  TRICARE is the health care program of the U.S. Department of Defense, providing benefits to 9.4 million active-duty, reserve and National Guard personnel, veterans and their d...
Oct 03, 2016 01:33 pm ET
Exact Sciences Announces Inclusion of Cologuard® in HEDIS Quality Measures
MADISON, Wis., Oct. 3, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS....
Sep 28, 2016 07:00 am ET
Exact Sciences to host third-quarter 2016 results webcast and call
MADISON, Wis., Sept. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Oct. 26, 2016, to discuss its third-quarter 2016 financial results....
Sep 16, 2016 05:15 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., Sept. 16, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 24,119 shares of common stock to 18 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in ac...
Aug 30, 2016 07:00 am ET
Exact Sciences to participate in the Baird 2016 Global Healthcare Conference
MADISON, Wis., Aug. 30, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in Baird's 2016 Global Healthcare Conference....
Aug 15, 2016 07:00 am ET
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries without Cost Sharing
MADISON, Wis., Aug. 15, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced that the Centers for Medicare and Medicaid Services (CMS) issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles. ...
Aug 11, 2016 07:00 am ET
Cologuard® Coverage Expands with Updated Policies from HCSC and Florida Blue
MADISON, Wis., Aug. 11, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Health Care Service Corp. (HCSC), the nation's fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population....
Aug 08, 2016 11:57 am ET
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
MADISON, Wis., Aug. 8, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Canaccord Genuity 36th Annual Growth Conference....
Jul 29, 2016 05:02 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., July 29, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 214,035 shares of common stock to 58 recently hired employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date.  The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement materi...
Jul 28, 2016 09:00 am ET
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
MADISON, Wis., July 28, 2016 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock.  The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares.  The offering is being underwritten...
Jul 26, 2016 06:00 am ET
Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
MADISON, Wis., July 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have order...
Jul 13, 2016 02:18 pm ET
NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures
MADISON, Wis., July 13, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced that the National Committee for Quality Assurance (NCQA) has proposed to broaden the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening to include Cologuard® on a three-year schedule....
Jun 29, 2016 07:00 am ET
Exact Sciences to host second-quarter 2016 results, annual meeting webcasts and calls
MADISON, Wis., June 29, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls to discuss its second-quarter 2016 financial results and for its annual stockholders meeting. ...
Jun 15, 2016 03:37 pm ET
Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations
MADISON, Wis., June 15, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Preventive Services Task Force (USPSTF) issued its final 2016 colorectal cancer screening recommendations and clarified the inclusion of Cologuard® (FIT-DNA) on equal standing among the other included screening tests....
Jun 15, 2016 10:56 am ET
Exact Sciences Statement Regarding Pending USPSTF Colorectal Cancer Screening Guidelines
MADISON, Wis., June 15, 2016 /PRNewswire/ -- Exact Sciences (Nasdaq: EXAS) issued the following statement today: "We are aware that the U.S. Preventive Services Task Force's final colorectal cancer screening guidelines are anticipated to be issued in the near future.  Exact Sciences will comment on the guidelines once they are released by the task force or published in the Journal of the American Medical Association."  ...
Jun 13, 2016 06:00 am ET
Collegium Announces Election of John A. Fallon, M.D. to Board of Directors
CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon, M.D. to the Board of Directors....
Jun 03, 2016 07:00 am ET
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
MADISON, Wis., June 3, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016.  In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success. ...
Jun 01, 2016 05:15 pm ET
Exact Sciences to participate in three investor conferences during June
MADISON, Wis., June 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June....
Jun 01, 2016 07:00 am ET
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
MADISON, Wis., June 1, 2016 /PRNewswire/ -- Exact Sciences Corp.  (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin. ...
May 05, 2016 05:15 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
MADISON, Wis., May 5, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 144,495 shares of common stock to 81 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in equal annual installments over periods ranging from one to four years.  The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement material...
May 05, 2016 07:00 am ET
Exact Sciences to participate in two investor conferences during May
MADISON, Wis., May 5, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May....
May 03, 2016 06:00 am ET
Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016
MADISON, Wis., May 3, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $14.8 million during its first quarter ended March 31, 2016, an increase of 244 percent compared to $4.3 million in the first quarter of 2015.  During the first quarter of 2016, the company completed approximately 40,000 Cologuard tests, an increase of more than 260 percent compared to approximately 11,000 tests completed in the same quarter of 2015. The cumulative number of physicians ordering Cologuard since launch expanded to more than 32,000....
Apr 12, 2016 06:30 am ET
Exact Sciences to host first-quarter 2016 results webcast and call
MADISON, Wis., April 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on May 3, 2016, to discuss its first-quarter 2016 financial results....
Mar 08, 2016 09:31 am ET
Covered Call Alerts For Apple, Exact Sciences, American Express, FireEye and Gilead Sciences Released By InvestorsObserver
CHICAGO, March 8, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, EXAS, AXP, FEYE and GILD. ...
Mar 01, 2016 04:30 pm ET
Exact Sciences to participate in events, conferences during March
MADISON, Wis., March 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences and other events during March....
Feb 26, 2016 04:05 pm ET
Exact Sciences Grants Inducement Restricted Stock Unit Awards to New Employees
MADISON, Wis., Feb. 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, the Compensation Committee of the Company's Board of Directors approved the reservation of 1,300,000 shares of common stock to be used exclusively for the grant of equity awards to individuals who were not previously employees of the Company (or following a bona fide period of non-employment), as an inducement equity award material to an individual's entry into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ...
Feb 25, 2016 06:00 am ET
Anthem BCBS Georgia and Virginia Contracted to Cover Cologuard as In-Network Service
MADISON, Wis., Feb. 25, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that under recently signed contracts, Cologuard will be covered as an in-network service for members of Anthem Blue Cross Blue Shield of Georgia and BlueCross BlueShield of Virginia. Both are the largest commercial health insurer in their respective states and part of the second-largest commercial health insurer in the United States....
Feb 24, 2016 06:00 am ET
Exact Sciences Reports Fourth Quarter and Full Year 2015 Results
MADISON, Wis., Feb. 24, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company reported revenues of $39.4 million as a result of completing more than 104,000 Cologuard tests for full-year 2015.  The company generated $14.4 million in revenues from approximately 38,000 completed Cologuard tests during the fourth quarter ended Dec. 31, 2015. ...
Feb 23, 2016 12:37 pm ET
Covered Call Alerts For PayPal Holdings Inc., 3D Systems, Exact Sciences, Second Sight Medical Products Inc. and Gogo Incorporated Released By InvestorsObserver
CHICAGO, Feb. 23, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PYPL, DDD, EXAS, EYES and GOGO....
Feb 23, 2016 06:36 am ET
Modeling Data Supports Cologuard Use Every Three Years
MADISON, Wis., Feb. 23, 2016 /PRNewswire/ -- A peer-reviewed analysis of the modeling data relied upon by the U.S. Preventive Services Task Force (USPSTF) when developing its draft colorectal cancer screening guidelines concludes that screening with Exact Sciences Corp.'s (Nasdaq: EXAS) Cologuard test on a three-year interval is equal or superior to screening with fecal blood tests on a two or three-year interval. The USPSTF considered fecal blood tests on an annual basis.  The modeling did not consider adherence when evaluating screening outcomes despite significant evidence that adherence ...
Feb 09, 2016 09:31 am ET
Covered Call Alerts For Pfizer Inc., Anglogold Ashanti Ltd, Skechers, Skyworks Solutions and Exact Sciences Released By InvestorsObserver
CHICAGO, Feb. 9, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, AU, SKX, SWKS and EXAS....
Feb 09, 2016 05:00 am ET
Exact Sciences to host fourth-quarter, full-year 2015 results webcast and call
MADISON, Wis., Feb. 9, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Feb. 24, 2016, to discuss its fourth-quarter and full-year 2015 financial results....
Feb 01, 2016 06:00 am ET
Exact Sciences to participate in Leerink Partners Global Healthcare Conference
MADISON, Wis., Feb. 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference....
Jan 25, 2016 08:42 am ET
Exact Sciences announces appointment of John A. Fallon, M.D., to company's board of directors
MADISON, Wis., Jan. 25, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that John A. Fallon, M.D., has joined the company's board of directors. Dr. Fallon brings more than 40 years of experience in health management, reimbursement, primary care and academic medicine to the board....